🇺🇸 FDA
Patent

US 9783806

TMPRSS6 iRNA compositions and methods of use thereof

granted A61PA61P25/00A61P25/14

Quick answer

US patent 9783806 (TMPRSS6 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P25/00, A61P25/14, A61P25/16, A61P25/18